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AbstrACt
Objective Three types of central venous access devices 
(CVADs) are routinely used in the delivery of intravenous 
systemic anticancer therapy (SACT): peripherally inserted 
central catheters (PICCs), subcutaneously tunnelled central 
catheters (Hickman-type devices) and totally implantable 
chest wall ports (Ports). This qualitative study, nested 
within a multicentre, randomised controlled trial, sought to 
explore patient acceptability and experiences of the three 
devices.
Design Eight focus groups were audio-recorded, 
transcribed and thematically analysed.
setting Six outpatient cancer treatment centres in the UK.
Participants Forty-two patients (20 female, mean age 
61.7 years) who had taken part or were taking part in the 
broader trial.
Intervention As part of the larger, randomised controlled 
trial, participants had been randomly assigned one of three 
CVADs for the administration of SACT.
results Attitudes towards all three devices were 
positive, with patients viewing their CVAD as part of their 
treatment and recovery. Participants with PICCs and 
Hickmans tended to compare their device favourably 
with peripheral cannulation. By comparison, participants 
with Ports consistently compared their device with PICCs 
and Hickmans, emphasising the perceived superiority of 
Ports. Ports were perceived to offer unique psychological 
benefits, including a greater sense of freedom and less 
intrusion in the context of personal relationships.
Conclusions Patient experiences and preferences have 
not been systematically used to inform policy and practice 
regarding CVAD availability and selection. Our research 
identified patterns of patient device preferences that 
favoured Ports, although this was not universal. Results 
of this study could improve support for patients and offer 
greater scope for incorporating patient perspectives into 
decision-making processes.
trial registration number ISRCTN44504648.
bACkgrOunD
Three types of central venous access devices 
(CVADs) are routinely used in the intravenous 
administration of systemic anticancer therapy 
(SACT; drugs administered for the treatment 
of cancer, including but not limited to cyto-
toxic chemotherapy): peripherally inserted 
central catheters (PICCs), tunnelled central 
catheters (Hickman-type devices) and totally 
implantable chest wall ports (Ports). These 
devices obviate the need for repeated periph-
eral cannulation, which patients find painful 
and distressing and which becomes more 
fraught as the veins thrombose with repeated 
use.1 Yet the three devices differ in important 
ways: PICCs are inserted into a peripheral 
vein in the upper arm, under ultrasound 
guidance. The end of the line sits outside the 
strengths and limitations of this study
 ► This is the first qualitative study concomitantly ex-
ploring patient experiences of the three most rou-
tinely used central venous access devices (CVADs) 
for the delivery of intravenous systemic anticancer 
therapy, namely Ports, peripherally inserted central 
catheters (PICCs) and Hickman-type devices.
 ► This research incorporates patient perspectives and 
experiences into the outputs of a large-scale, ran-
domised controlled trial comparing PICC, Hickman 
and Port devices in terms of clinical efficacy, safety 
and cost-effectiveness.
 ► This paper offers important insights and informa-
tion of interest to clinicians involved in the selection 
and use of CVADs, to those involved in the care of 
patients requiring long-term venous access, and to 
patients themselves, including particular benefits of 
Ports and a pattern of preference for these devices.
 ► Although we aimed to recruit patients with cancer 
with a range of histological types, from our available 
population it was possible to recruit only one patient 
with haematological cancer, and our sample mainly 
consisted of patients diagnosed with solid malig-
nancies, predominantly colorectal cancers.
 ► Like all qualitative research, this study is con-
text-bound, and a consideration of the context in 
which the study was carried out—the UK public 
health system—is essential for the interpretation of 
these findings.
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body, extruding above the elbow. Hickman-type devices 
are placed through an incision near the collarbone 
with the end of the catheter tunnelled under the skin, 
emerging from a second, lower chest wall incision. Ports 
are completely enclosed systems without external lines, 
implanted in the subcutaneous tissue of the chest wall. 
Needle puncture is required for access each time they are 
used.
While available evidence suggests that patients tend to be 
satisfied with all three types of device (PICC,2–4 Hickman5 6 
and Port7–12), there is little indepth knowledge about what 
it takes to live well with one of these devices in place. More-
over, the distinct characteristics of each device together 
with differing care and maintenance requirements could 
imply meaningful differences in patient experiences. To 
date, empirical evidence concerning differences and simi-
larities in patient experiences remains scarce and incon-
clusive. In a prospective randomised controlled trial, Patel 
et al13 found no significant differences in terms of quality 
of life, yet participants commented that “the question-
naire did not ask about several aspects of quality of life 
which were affected by the central venous catheter, for 
example, showering, bathing and swimming.” Comparing 
experiences of Ports and Hickman-type devices, Wu et 
al14 found that Ports were associated with more positive 
and less negative patient-reported outcomes. Comparing 
patient-reported experiences of dual-lumen Ports and 
Hickman-type devices, Johansson et al15 found that while 4 
out of 15 patients with Ports experienced extensive subcu-
taneous bleeding leading to premature study closure, 
patient questionnaires demonstrated that, overall, patients 
with Ports thought about their device less and reported 
less disruption when dressing and bathing.
Clinical and local service factors determine whether 
and which CVADs are made available to patients. Where 
more than one device is appropriate and available, and 
despite recent growth in patient-centred approaches, 
device selection and patient support tend to prioritise 
clinical aspects often to the exclusion of patient experi-
ence. In this paper, we report findings from a multicentre 
qualitative study which was nested within the Cancer And 
Venous Access (CAVA) trial. Involving over 1000 patients 
at 17 UK sites, CAVA constitutes the largest randomised 
controlled trial comparing PICC, Hickman and Port 
devices in terms of clinical efficacy, safety and cost-effec-
tiveness. The present qualitative component incorporates 
patient experiences and perspectives into the outputs of 
the clinical trial.
MethODs
Design
This is a qualitative focus group study. Reporting is based 
on the Consolidated criteria for Reporting Qualitative 
research.16
sampling and recruitment
Forty-two patients who had enrolled on the CAVA trial 
participated in eight focus groups. As part of the trial, 
participants met the following criteria: aged ≥18 years, 
receiving or due to receive SACT of at least 12 weeks’ 
duration, and clinical team uncertain as to which CVAD 
is optimal for this indication. They had also opted to 
have their particular CVAD type allocated randomly. 
Participants were sampled from the six largest recruit-
ment centres: Glasgow (lead centre), Leeds, Manchester, 
Newcastle, Durham and London. Three further partic-
ipants who had agreed to participate were too unwell 
to attend, one each at Leeds, Durham and London. A 
purposive sample of participants was identified by local 
trial staff at each site (table 1). To include a range of 
perspectives and experiences, participants at each site 
were chosen for maximum variation in terms of age, sex, 
cancer diagnosis, device allocation, as well as positive and 
negative clinical experiences with CVADs. The largest 
group of patients had colorectal cancer as infusional regi-
mens commonly used in this patient group frequently 
require long-term central venous access. To facilitate both 
comparison and device-specific examination, four groups 
were single-device groups (participants within each had 
been randomly allocated the same device type) and four 
were mixed-device groups (participants had been allo-
cated different devices). After the eighth focus group, it 
was determined that data saturation had been achieved, 
that is, no substantive new information was generated and 
additional focus groups would be of no further benefit. 
Across groups, some participants had experiences of 
different lines prior to CAVA. Eligible participants were 
initially contacted by local trial nurses with whom they 
had prior contact and who provided information sheets 
in person or by mail.
Procedure
Focus groups were held between August 2016 and 
December 2017. Discussions took place in quiet meeting 
rooms in the trial centres and were moderated by the lead 
author (CR), a female psychologist (PhD) and experi-
enced qualitative researcher who had no prior relationship 
with participants. A trial nurse attended part of one focus 
group (Leeds) to address patient queries, otherwise no 
other persons were present. Prior to each session, details 
about data collection, analysis and use were discussed, 
and informed consent was obtained. The moderator 
started by explaining her own background and role in the 
trial. She then reminded participants about the purpose 
of the broader trial and current focus group, using A4 
cards depicting each device type and reiterating current 
clinical equipoise. A focus group guide was used to ensure 
that all relevant topics would be addressed (box 1). Topics 
included CAVA trial participation and day-to-day experi-
ences relating to their device. To create a communication 
situation resembling a ‘naturally occurring interaction’,17 
interference with the discussion was kept to a minimum. 
Focus group discussions lasted approximately 1 hour and 
were audio-recorded with participant permission. To 
assist with transcription and analysis, relevant field notes 
were compiled after each focus group.
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Analysis
Recordings were transcribed, anonymised and uploaded 
to the QSR NVivo V.10 software. Data were analysed using 
thematic analysis, ‘a method for identifying, analysing 
and reporting patterns (themes) within data’.18 First, 
transcripts were read and reread to ensure familiarity. A 
coding framework was developed based on patterns and 
repeated topics identified in the data. Data were coded, 
and coded chunks of data were grouped into initial 
themes. These processes were conducted by a single 
researcher in the first instance and reviewed by two further 
researchers at different stages. Data were then reread and 
the appropriateness of themes interrogated. Particular 
attention was paid to similarities and differences across 
devices types, and to discrepancies between developed 
themes and the data. As a final step, the specifics of each 
theme were refined, and clear definitions for each theme 
were formulated.
Patient and public involvement
Patients were not directly involved in the design of this 
study. However, research aims, focus group materials 
and data analysis were closely informed by pretrial focus 
groups with patients who had experiences of CVADs 
in the context of SACT.19 These focus groups explored 
topics of importance to patients with respect to venous 
access and SACT, as well as their views on participation in 
a randomised controlled trial comparing CVADs.
results
Our analysis identified three main themes, presented in 
detail below.
Acceptability of CVADs
All devices were well accepted by participants, and atti-
tudes towards all three were generally positive. CVADs 
were regarded as less impactful than other aspects of 
participants’ journeys (eg, SACT, surgical interventions) 
and the effects of their illness, more broadly. Patients who 
Table 1 Demographic and clinical characteristics of study 
participants
Age in years
  Mean 61.7
  Median 61.5
  SD 8.6
  Range 45–79
Sex
  Male 22
  Female 20
Type of cancer
  Colorectal 24
  Breast 5
  Ovarian 4
  Pancreatic 3
  Endometrioid 2
  Lung 1
  Oesophageal 1
  Prostate 1
  Acute myeloid leukaemia 1
CVAD use
  Hickman-type 11
  PICC 15
  Port 16
Number of CVADs prior to CAVA participation
  None 30
  At least one, inserted >3 months prior to study 
entry
11
  At least one, inserted <3 months prior to study 
entry
1
Weeks elapsed since consenting to participate in 
the trial
  Mean 40.9
  SD 34.2
  Range 3–137
CAVA, Cancer And Venous Access; CVAD, central venous access 
device; PICC, peripherally inserted central catheter. 
box 1 Questions included in the focus group guide
Question 1: What factors did you take into account when 
considering whether to participate in this trial?
 ► Prompt: Did you have any doubts?
 ► Prompt: What discussion did you have with your clinician/family?
Question 2: how did you feel about your device/line being 
selected by randomisation (by chance)?
 ► Prompt: What previous experiences did you have with venous ac-
cess before you had your line inserted?
 ► Prompt: Did you have a preference for any particular device prior to 
being randomised?
Question 4: What were the positive/negative aspects of 
your device?
 ► Prompt: How did you feel about your device? (What did it represent 
to you?)
Question 5: In what ways did your device affect your 
everyday life?
 ► Prompt: What sorts of adjustments did you have to make?
 ► Prompt: Did it have an effect on the social aspects of your life (eg, 
with family and broader)?
 ► Prompt: Did you experience any problems with your device?
Question 6: Is there anything else you would like to say 
about your device?
 ► Prompt: What is the most important thing for someone who is about 
to have a line implanted to know?
 ► Prompt: What would you like clinicians/NHS to know about your 
experience?
NHS, National Health Service.
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had experienced SACT via peripheral cannulation said 
that their device made administration less painful and 
easier (both for themselves and for the staff). Participants 
tended to frame satisfaction in terms of the role of their 
device in their treatment and in their overall journey: “It’s 
part of my treatment, so it’s part of my life, it’s there” (Female, 
PICC).
When expressing satisfaction with their device, many 
participants referred to having had a problem-free 
experience. Our sample also included people who had 
experienced various difficulties with each of the devices, 
including painful placement or unsuccessful placement 
attempts, thrombus, infection and device malfunction. 
Notably, even these patients reported being satisfied with 
their overall experience. Partial or minor malfunctions 
did not appear to affect acceptability or satisfaction, as 
long as the device remained functional.
Participant 1: It really doesn’t bother me. (Male, Port)
Participant 2: As long as you can have your treatment 
through, it doesn’t. (Female, Port)
living with a CVAD
Notwithstanding acceptance, living with a CVAD 
presented distinct challenges, which necessitated mean-
ingful adjustments and adaptations. While the experi-
ence of individual participants differed substantially, 
we provide an inclusive account of the wide range of 
experiences described, highlighting points of difference 
between devices.
Practical challenges
Participants with PICCs and those with Hickman-type 
devices described comparable challenges and responses, 
which centred on keeping their external line clean, 
secure and comfortable. At a minimum, most reported 
needing to change the ways in which they bathed or slept. 
To keep their line dry, participants described sourcing 
and using various waterproof covers, or innovating their 
own solutions using household items (eg, “I put cling-film 
on it” (Male, PICC)). Some described adopting a consci-
entious approach to choosing clothing that could both 
conceal and accommodate their devices: “I certainly think 
about what I’m going to wear’"(Female, Hickman). Here too, 
they exhibited resourcefulness; they described impro-
vising protective covers and finding ways of securing lines 
with underclothing or sterile dressings (eg, “I had an old 
pair of tights I used to cut them and I had different colours and 
that worked fine” (Female, PICC)). These difficulties were 
heightened when portable SACT infusion pumps were 
attached to devices for treatment, preventing participants 
from securing or covering their line in the usual way.
Quite often I slept downstairs on the couch because 
I was worried about my partner who does [big arm 
movements] you know in his sleep and I thought 
it’s better with these wires going from here and up 
through your jammies so I just slept downstairs so 
that’s what I did on those nights [when pump was at-
tached]. (Female, PICC)
For participants with Ports, experiences varied more 
markedly depending on whether a portable SACT 
pump was attached to their device. With pumps in place, 
participants with Ports experienced the same challenges 
described by those with PICCs and Hickman-type devices. 
Most of the time, without a pump attached, participants 
experienced few concerns regarding everyday activities, 
although some reported feeling cautious about their 
device, especially early on and during sleep. In general, 
participants with Ports claimed that based on their obser-
vations or direct experiences (some had experienced 
different devices prior to CAVA), as compared with PICCs 
and Hickman-type devices, Ports were more discreet, 
more secure, less disruptive of hobbies and activities, and 
easier to live with and maintain.
It’s just ease of use and the fact that it’s not in usage 
24/7 for months on end like the Hickman lines size 
of a packet of fags [cigarettes] hanging on your chest, 
or the cannula sticking out your arm constantly that 
you have to protect and worry about. (Male, Port)
Gaps in knowledge
Across all three devices, the adjustments and adapta-
tions described by participants were often associated with 
moments of uncertainty regarding proper care of their 
device or moments where their device complicated ordi-
nary activities.
Well, it’s like the showering. ‘Cause you don’t know 
until you’re home and you think ‘Oh, right. How am 
I gonna get around this now?’ So you suss it out for 
yourself. (Female, Port)
Where participants were unable to find a solution to 
a particular problem, they sometimes gave up and disre-
garded care advice: “I abandoned trying to keep it dry and I 
was just very naughty and I would shower regardless” (Female, 
PICC). Some of those who found that their device was 
affected by seat belts reported wearing their belt in uncon-
ventional ways, uncertain if what they were doing was safe 
or legal: “There is a question about eh, you know, is it safe? Is it 
legal?” (Male, Port). Participants with Ports demonstrated 
a unique knowledge gap; many were unclear as to how 
long their device would remain in place and what this 
might mean for ongoing care and support.
In all, participants received sufficient information 
concerning device placement and critical aspects of line 
care, but were generally underprepared for living with a 
device in place. Some explicitly called for better informa-
tion provision for future patients.
When someone gets a line there should be some 
information. […] At least you should be told: ‘You 
need to keep it clean and dry so buy this thing for 
about £15. If you want, there’s a cover that makes it 
a bit more discreet’. That sort of thing. There’s no 
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support with that. I’d like to think the people that 
follow us will get advice that we’ve not been given. 
(Male, PICC)
Clinical care
Participants spoke at length about interactions with clin-
ical staff, particularly those encountered outwith oncology 
departments—mainly community (district) nurses, but 
also staff at local clinics or other hospital departments. 
These discussions centred on a lack of staff experience 
and knowledge regarding CVADs, which led to delays and 
inconveniences and was an additional source of worry for 
some. While this applied to all devices, it was especially 
pervasive in the case of Ports: “The biggest problem with me is 
the district nurses” (Female, Port).
Emotional and psychological impact
The practical benefits associated with their lack of 
external lines (ie, less visible, easier maintenance) meant 
that Ports appeared to be less psychologically burden-
some. In particular, participants with Ports repeatedly 
stressed that it was easy for them to “forget” about their 
device for days or weeks at a time. Participants described 
feeling “free” between rounds of treatment.
This thing [Port] is kind of a plug and play approach. 
Plug it in, introduce the chemicals, take it out, chuck 
it away and you are free, it’s nothing, it’s as if it wasn’t 
there. (Male, Port)
While some participants with PICCs and Hickman-type 
devices also described being able to completely forget 
about their device, the majority were reminded of it 
several times daily, mostly when bathing and dressing. 
One participant compared his current Port and previous 
PICC in this regard, explaining that he had been aware 
of his PICC “24/7” and had come to resent his treat-
ment because he conflated treatment and mode of 
delivery (PICC). By contrast, he could forget about his 
Port entirely and no longer resented treatment. In fact, 
he found the lack of external line so beneficial that he 
described the experience of having his portable pump 
disconnected in the following terms:
As soon as that [portable pump] came off, bang, that 
was it. You almost felt alive again. Because it just de-
taches everything. It all disappears. And mentally as 
well as physically you can begin to forget it because 
you don’t really know it’s there. And I think that’s 
a huge difference. It sort of lifts you back up again. 
(Male, Port—prior experience of PICC)
Participants also discussed the effects of CVADs on rela-
tionships and intimacy and found the Port to be beneficial in 
important ways. External lines, but not Ports, caused worry 
in the context of close physical contact. One participant 
with a Hickman-type device explained that it had affected 
her relationship with her husband because its external lines 
made her feel unattractive. Another explained that her 
external line had got in the way when she and her husband 
needed to comfort each. She talked about the importance 
of moments of physical comfort in the context of cancer.
But even, you know, my husband just putting his arm 
across me to give me a cuddle at night-time and we 
were denied that because he was so worried that he 
touched it and I was equally worried that it would be 
caught up as well. And it was when you need it most, 
some comfort, you were denied that comfort because 
of this line hanging out. (Female, Hickman—prior 
experience of Port)
Participants with different devices expressed different sets 
of emotions when discussing their decision to show their 
device to others or to conceal it. For instance, participants 
with PICCs and Hickman-type devices expressed discomfort 
regarding the appearance of their device and how it would 
make others feel to see it.
I don’t like seeing a tube going into my chest, so I 
don’t imagine other people want to see it either. 
(Female, Hickman)
In our sample, this sentiment was not echoed by partic-
ipants with Ports. Among these participants, some talked 
about showing their device to others in terms of sharing 
a sense of awe or fascination with their device. Some even 
expressed humour; three participants with Ports (currently 
or previously) mentioned nicknames—based on the idea 
of a button—that they and others (friends, family) used for 
their device, for example, “She [young daughter] calls it my 
magic button!” (Male, Port).
Patterns of preference
Among our sample, participants tended to prefer their 
own device, and most stated that if they had to choose a 
CVAD they would choose the one they currently had. 
Noticeable differences between devices were evident with 
regard to how satisfaction and preferences were formulated 
and expressed. For instance, we observed differences in 
the comparators participants used when discussing device 
satisfaction. Participants with PICC and Hickman-type 
devices tended to compare their devices (favourably) with 
peripheral cannulation. Participants in a Hickman-only 
focus group compared Hickman and PICCs, preferring the 
former which they felt was less obtrusive. Unless prompted, 
participants with either of these devices tended not to make 
comparisons with Ports. When prompted, there was ambiva-
lence. Some were unsure about the idea of a needlestick for 
device access or, among those with PICCs, a device in their 
chest. Some claimed to lack sufficient knowledge about 
Ports to compare. Others, while happy with their current 
device, professed an interest in Ports. By comparison, 
participants with Ports consistently compared them with 
PICCs and Hickman-type devices and explicitly regarded 
Ports as superior CVADs.
The whole three [CVADs] were an option and I was 
hoping that it would be the Port just because you 
didn’t see anything. (Female, Hickman)
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Furthermore, participants with PICCs and Hickman-type 
devices tended to express satisfaction with their device in 
personal terms. In the following extract, when ‘Participant 
1’ was asked if he would recommend PICCs to others, he 
was reluctant, stressing the personal nature of his prefer-
ence. This was not the case with ‘Participant 2’ who had a 
Port device.
Participant 1: Well I wouldn’t suggest, I wouldn’t give 
anybody advice on it because it’s up to them what that 
they do, it’s everybody’s personal choice what they 
like, em, but I would just say, well I find this a lot eas-
ier you know, so that’s…[to Participant 2] obviously 
you’ve had a Port… (Male, PICC)
Participant 2: I would recommend the Port. (Female, 
Port)
As illustrated here, participants who preferred Ports 
were more forthright in their preferences, which tended 
to be based on characteristics of the device itself, rather 
than familiarity or personal factors. This forthrightness was 
noted with interest by one participant with a PICC:
Loving the fact that the Port owners are really enthu-
siastic, there is this sense of like evangelical ‘yeah this 
is great’. Whereas with the PICC line we are all in-
different, different experiences, it’s not as clear cut, 
whereas you guys are. (Male, PICC)
Participants who could directly compare Ports and other 
devices were unequivocal in their preference for Ports, and 
positive regard for Ports held, even among those who had 
experienced painful placement procedures and device 
complications.
So it [Port] hasn’t worked for me, but if it had worked 
I would think it was the best one. (Female, Port)
Reflecting on the provision of Ports by the National 
Health Service, participants advocated for greater access to 
Ports, arguing that benefits justify additional costs.
And I feel quite strongly the very small difference 
between the Hickman-line costs and Port costs and 
the overall benefits to people who are going, suffer-
ing enough anyway, their life should be made easier. 
And it’s a small difference, you know. And as I say I 
have had the benefit of trying these different things, 
and I find just, there’s no comparison. (Female, 
Hickman—prior experience of Port)
COnClusIOns
To the best of our knowledge, this is the first qualitative 
study concomitantly exploring patient experiences of the 
three most routinely used CVADs for the delivery of intrave-
nous SACT, namely Ports, PICCs and Hickman-type devices. 
Our study was nested within a large-scale, randomised 
controlled trial and recruited a diverse sample of patients 
from six different UK centres. Our results resonate with 
prior findings suggesting that all three CVADs are generally 
well accepted by patients.2–12 More than that, our analysis 
allowed for meaningful comparisons between experiences 
of different devices. We found that, while participants were 
satisfied with all three devices, focus groups highlighted 
key practical benefits of Ports (ie, perceived to be less 
conspicuous, less disruptive and easier to maintain), which 
had important impact on psychological and emotional 
well-being. The unique psychological benefits of Ports, 
including a greater sense of freedom and less intrusion in 
the context of personal relationships, have not been previ-
ously described in the literature.
Prior qualitative work focusing on patient experiences 
with PICCs has suggested that continuing normal everyday 
activities (eg, bathing, dressing), although possible for 
most, can depend on disruptive adjustments and is not 
without worry.20–22 Participants in our study, regardless 
of device type, extensively discussed similar challenges, 
although these applied to a much lesser extent to patients 
with Ports (except when portable pumps were attached). 
Fundamentally, all three types of device necessitated 
meaningful adjustments, with implications for patient 
well-being, as well as device care and maintenance. Our 
work points to the resourcefulness and resilience of 
patients; when conventional solutions did not work or 
were inadequate, participants innovated ways to deal with 
practical problems (eg, using household items to keep 
their line dry). This also highlights important ways in 
which patients could be better supported with practical 
guidance regarding bathing, driving and other aspects 
of device maintenance, as well as locally available prod-
ucts and resources. Patients’ enthusiasm for speaking 
with fellow patients about their CVADs in the focus group 
context could indicate that providing forums for mutual 
support and knowledge exchange among patients might 
be one way to meet these needs.
In our sample, all participants with Ports, many of 
whom also had prior experience of other CVADs, were 
generally inclined to advocate for Ports and make the 
case that these should be more widely available. However, 
while a small number of participants with PICC and Hick-
man-type devices expressed preferences for or equal 
interest in Ports, participants tended to favour their own 
device over others. This suggests either that our partic-
ipants had adjusted well to their device, or that prefer-
ences for Ports—although exhibited in a stronger and 
more consistent way—might not be universal. Thus, 
where medically appropriate, patients should be offered 
a choice, and device selection should be a collaborative 
process between patients and clinicians.23
Qualitative research is context-bound, and a consider-
ation of the context in which the study was carried out 
is essential for the interpretation of these findings. Our 
study context was the UK public health system. Within 
this system, Ports are less widely available than PICCs 
or Hickman-type devices and participants were aware of 
this situation. To some extent, the particular advocacy 
for Ports observed within our sample might have been a 
response to these circumstances (similar advocacy was also 
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observed at centres where Ports were more widely avail-
able). Relatedly, the limited use of Ports within the public 
health system is closely associated with a lack of training 
and expertise among community nurses and other clinical 
staff19—the factor identified by several participants with 
Ports as the most problematic aspect of their experience 
with the device. All of these factors might have affected, to 
some extent, how participants formulated and expressed 
their opinions and preferences. Further examination of 
this topic in different health service contexts is warranted.
study limitations
The use of CVADs is heavily dependent on the type of SACT 
required. Our sample consisted mainly of patients diag-
nosed with solid malignancies, most frequently colorectal 
and breast cancers, the two cancers most commonly 
requiring a CVAD. Extrapolation of the findings of this 
study to other populations may not be appropriate. In addi-
tion, our sample is distinct in that all of our participants 
had agreed to have their particular device type allocated at 
random; a discussion of the process of device selection was 
outside the scope of this paper.
Clinical implications
This work comes at a time of expanding interest in the 
potential impact of CVADs. In the UK, cancer treatment has 
traditionally been associated with Hickman-type devices. 
More recently, there seems to be a shift in favour of PICCs, 
as more centres introduce nurse-led PICC services. In 
addition, Ports have tended to be less available to patients 
(primarily owing to greater upfront costs), but this seems to 
be changing too, especially in private healthcare settings. 
Our findings that Ports conferred unique benefits to and 
were advocated by patients in our sample are important 
in light of these trends. The results of this study could be 
used to improve support for patients living with CVADs 
and, where more than one device is available and clinically 
appropriate, offer greater scope for incorporating patient 
perspectives and needs into decision-making processes.
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